Elevated levels of novel biomarker TDP-43 in Alzheimer's disease (AD) show the therapeutic potential of NeuroSense's combination platform
Phase 2 double-blind proof-of-concept clinical study expected to commence in H1 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease (AD). Preliminary results from the study, showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. Based on these encouraging preliminary results, NeuroSense expanded the study with a larger healthy control group to further validate the results.
https://finance.yahoo.com/news/neurosense-therapeutics-reports-positive-final-135200403.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.